This site is intended for healthcare professionals in Belgium and Luxembourg.
1. Reblozyl® (luspatercept) [Summary of Product Characteristics (SmPC)]. Bristol Myers
Squibb Pharma EEIG, Dublin, Ireland. SmPC in French, SmPC in Dutch.
2. Suragani RN, Cadena SM, Cawley SM, et al. Transforming growth factor-β superfamily ligand trap
ACE-536 corrects anemia by promoting late-stage erythropoiesis. Nat Med. 2014;20(4):408-414.
Attie KM, Allison MJ, McClure T, et al. A phase 1 study of ACE-536, a regulator of erythroid
differentiation, in healthy volunteers. Am J Hematol. 2014;89(7):766-770.
4. Institut national
d'assurance maladie-invalidité (INAMI).
https://ondpanon.riziv.fgov.be/SSPWebApplicationPublic/fr/Public/ProductSearch. Accessed December
For your adult patients with MDS- or B-thalassemia-associated anemia
With Reblozyl®▼- the first and only erythroid maturation agent- you can reduce or even eliminate patients’ red blood cell (RBC) transfusion dependence. 1-3
Reblozyl®▼ is reimbursed in Belgium as of August 1st 2021 for the treatment of adult Patients:
The request has to be submitted via eHealth.
The maximum reimbursed posology is 1,75 mg/kg every 21 days for MDS and 1,25 mg/kg every 21 days for beta-thalassemia.
Reblozyl®▼ treatment will stop being reimbursed if:
▼This medicinal product is subject to additional monitoring. This will allow quick Identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Before prescribing Reblozyl®▼, please refer to the SmPC.
View the Eu SmPC in French, SmPC in Dutch.